N-[3-CYANO-1-[2,6-DICHLORO-4-(TRIFLUOROMETHYL)PHENYL]-4-[(TRIFLUOROMETHYL)SULFINYL]-1H-PYRAZOL-5-YL]-1-(BETA-D-GLUCOPYRANOSYL)-1H-1,2,3-TRIAZOLE-4-METHANAMINE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	LRKLXTAYSOAJNQ-QXRLNHOPSA-N
Smiles	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)n2cc(CNc3c([S+]([O-])C(F)(F)F)c(nn3c4c(Cl)cc(cc4Cl)C(F)(F)F)C#N)nn2
InChI	InChI=1S/C21H17Cl2F6N7O6S/c22-9-1-7(20(24,25)26)2-10(23)13(9)36-18(17(11(3-30)33-36)43(41)21(27,28)29)31-4-8-5-35(34-32-8)19-16(40)15(39)14(38)12(6-37)42-19/h1-2,5,12,14-16,19,31,37-40H,4,6H2/t12-,14-,15+,16-,19-,43?/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C21H17Cl2F6N7O6S
Molecular Weight	680.36
AlogP	4.28
Hydrogen Bond Acceptor	11.0
Hydrogen Bond Donor	5.0
Number of Rotational Bond	9.0
Polar Surface Area	210.78
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	43.0

Assay Description	Organism	Bioactivity
Drug metabolism in adult Ricinus communis (castor bean) roots assessed as compound conversion to fipronil at 2 mM measured 48 to 72 hr post treatment	Ricinus communis	None
Drug metabolism in adult Ricinus communis (castor bean) lower stem assessed as compound conversion to fipronil at 2 mM measured 48 to 72 hr post treatment	Ricinus communis	None
Drug metabolism in adult Ricinus communis (castor bean) upper stem assessed as compound conversion to fipronil at 2 mM measured 48 to 72 hr post treatment	Ricinus communis	None
Drug metabolism in adult Ricinus communis (castor bean) apical leaves assessed as compound conversion to fipronil at 2 mM measured 48 to 72 hr post treatment	Ricinus communis	None
Drug metabolism in adult Ricinus communis (castor bean) roots assessed as compound conversion to fipronil at 2 mM measured 48 to 72 hr post treatment by HPLC-MS method	Ricinus communis	None
Drug metabolism in adult Ricinus communis (castor bean) lower stem assessed as compound conversion to fipronil at 2 mM measured 48 to 72 hr post treatment by HPLC-MS method	Ricinus communis	None
Drug metabolism in adult Ricinus communis (castor bean) upper stem assessed as compound conversion to fipronil at 2 mM measured 48 to 72 hr post treatment by HPLC-MS method	Ricinus communis	None
Drug metabolism in adult Ricinus communis (castor bean) apical leaves assessed as compound conversion to fipronil at 2 mM measured 48 to 72 hr post treatment by HPLC-MS method	Ricinus communis	None
Insecticidal activity against Plutella xylostella (diamondback moth) third-instar larvae measured 24 hr post dose by leaf disk dipping assay	Plutella xylostella	16.73 ug.mL-1
Phloem mobility in Ricinus communis (castor bean) seedlings phloem sap assessed as drug level at 200 uM measured 7 hr post dose by DiBAC4 indicator based flow cytometry relative to untreated control	Ricinus communis	0.45
Phloem mobility in Ricinus communis (castor bean) seedlings phloem sap assessed as drug level at 200 uM by HPLC-MS method	Ricinus communis	None
Phloem mobility in Ricinus communis (castor bean) seedlings phloem sap assessed as drug level at 200 uM measured 3.5 hr post dose by DiBAC4 indicator based flow cytometry relative to untreated control	Ricinus communis	0.25
Phloem mobility in Ricinus communis (castor bean) seedlings phloem sap assessed as drug level at 200 uM measured 8 hr post dose by DiBAC4 indicator based flow cytometry	Ricinus communis	None

Cross References

Resources	Reference
ChEMBL	CHEMBL2228802
PubChem	76333204

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).